Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

23.63
-0.0900-0.38%
Post-market: 24.000.3700+1.57%19:41 EDT
Volume:928.30K
Turnover:22.06M
Market Cap:2.08B
PE:-5.40
High:24.34
Open:24.01
Low:23.55
Close:23.72
52wk High:47.65
52wk Low:22.30
Shares:88.16M
Float Shares:66.03M
Volume Ratio:0.56
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3763
EPS(LYR):-2.2900
ROE:-80.88%
ROA:-46.18%
PB:3.78
PE(LYR):-10.32

Loading ...

Mineralys Therapeutics Confronts Heightened Refinancing and Liquidity Risks as 2031 Debt Maturity Looms

TIPRANKS
·
Aug 13

Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 58,785.3 in Common Shares

Reuters
·
Aug 13

Mineralys Therapeutics Names James J. Ferguson III as Chief Medical Officer in Form 3 Beneficial Ownership Filing

Reuters
·
Aug 13

Goldman Sachs Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Aug 12

Mineralys Therapeutics Publishes Corporate Presentation on Lorundrostat for Uncontrolled, Resistant Hypertension and Cardiorenal Diseases

Reuters
·
Aug 12

Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Mineralys Therapeutics Q2 Loss Widens

MT Newswires Live
·
Aug 12

Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss

MT Newswires Live
·
Aug 12

Mineralys Therapeutics Catat Rugi Bersih Kuartal II FY26 Melebar Jadi USD 241,07 Juta; Belanja R&D Melonjak Jadi USD 221,38 Juta

Reuters
·
Aug 12

Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 12

Mineralys Therapeutics to Report Q2 Results, Host Conference Call

Reuters
·
Aug 04

Mineralys Therapeutics Grants Inducement Equity Awards to New Hires Under 2025 Plan

Reuters
·
Jul 28

Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 28

Mineralys Chief Commercial Officer Eric Warren Disposes of $199,900 in Common Shares

Reuters
·
Jul 24

Mineralys CMO David Malcom Rodman Disposes of 416 Common Shares Worth $11,036.48

Reuters
·
Jul 21

Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 559,234 in Common Shares

Reuters
·
Jul 16

Mineralys CMO David Malcom Rodman Sells 2,171 Common Shares Worth $65,781.30

Reuters
·
Jul 11

Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?

Simply Wall St.
·
Jul 06

Have Insiders Sold Mineralys Therapeutics Shares Recently?

Simply Wall St.
·
Jul 03

Mineralys Therapeutics (MLYS) Left Key Russell Indexes, Is The Stock Still Below Fair Value?

Simply Wall St.
·
Jul 02